APOKYN (apomorphine hydrochloride injection) is indicated for the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing-off and unpredictable on-off episodes) associated with advanced Parkinson's disease. APOKYN has been studied as an adjunct to other medications.

Important Safety Information
The concomitant use of apomorphine with drugs of the 5HT₃ antagonist class is contraindicated.

Apomorphine should not be administered intravenously.

At the recommended doses of apomorphine, severe nausea and vomiting can be expected. Therefore, trimethobenzamide should be started 3 days prior to the initial dose of apomorphine and continued for at least 2 months.

Caution is recommended when administering apomorphine to patients with increased risk of QT prolongation.

Apomorphine can cause hypotension, orthostatic hypotension, and syncope. Apomorphine has the potential to exacerbate coronary (and cerebral) ischemia.

There have been literature reports of patients treated with apomorphine who suddenly fell asleep while engaged in activities of daily living.

The most common adverse events seen in controlled trials were yawning, dyskinesias, nausea and/or vomiting, somnolence, dizziness, rhinorrhea, hallucinations, edema, chest pain, increased sweating, flushing, and pallor.